A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy

Update Il y a 4 ans
Reference: EUCTR2005-001166-13

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the safety, tolerability and recommended dose of abiraterone acetate administered orally, by continuous once-daily administration in patients with HRPC. To determine the effect of abiraterone acetate on the pituitary-adrenal-gonad endocrine axis and on adrenal hormones by evaluating serum levels of testosterone and its precursors. To evaluate the efficacy of abiraterone acetate in HRPC at recommended dose.


Inclusion criteria

  • Hormone refractory prostate cancer

Links